Skip to main content
. 2019 Jan 2;9(1):7. doi: 10.3390/metabo9010007

Figure 1.

Figure 1

Overview of the workflow applied. MCF-7 breast cancer cells were treated either with the Cyclin-dependent kinases (CDK)4/6 inhibitor palbociclib, the estrogen receptor antagonist fulvestrant, or a combination of both drugs. Cells were extracted and analyzed after two days, seven days (without refeed), and seven days (with refeed).